Ayrmid has not obtained the necessary financing to support its unsolicited, non-binding written proposal to purchase the company, Bluebird said.

CHMP reversed its initial recommendation for the EC to not authorize the drug due to the risk of side effects like ARIA.

The firm submitted data from a registrational study showing the drug's activity in adult and adolescent patients with NTRK fusion-positive solid tumors.

Amid an 18 percent increase in cancer drug sales, J&J executives shared hopes that recent overall survival data for the drug combo will be practice changing.

In the trial, researchers are evaluating Scancell's DNA cancer vaccines SCIB1 and iSCIB1+ alongside immunotherapy.

After VERVE-102 showed the ability to lower LDL-C and PCSK9 in the Heart-2 trial, the firm said it will advance the therapy to a Phase II study later this year.

On the heels of its acquisition by Ocuphire Pharma, Opus is planning next steps for its Leber congenital amaurosis type 5 ...

ACMG, NSGC, and others in the genetics community are monitoring whether the widely used online clinical genetics database ...

After an earlier trial showed patients with elevated levels of a cardiac stress marker benefited from its cell therapy, the firm shifted focus to this subset.

The biotech firm closed an oversubscribed Series C funding round, proceeds from which it will use to advance ATSN-201 and its ...

Researchers urged hospitals to set up processes for updating pharmacogenomic results, but it's unclear how frequently that ...